dual incretin agonist · GIP / GLP-1
tirzepatide, in research terms
Also known as LY3298176.
Tirzepatide (LY3298176) is the reference compound for dual-incretin research — the first widely-studied peptide to co-agonise the GIP and GLP-1 receptors from a single molecule. It is the baseline that newer triple agonists are measured against.
what it is
Tirzepatide is a synthetic peptide that acts as an agonist at both the GIP and GLP-1 receptors — a "dual agonist" or "co-agonist". A single molecule engaging two incretin receptors is the idea it established, and it anchors the metabolic range.
the mechanism, at a research level
GLP-1 receptor agonism is the most-studied incretin mechanism in glucose-regulation and appetite research. GIP receptor agonism is the second incretin arm; co-engaging it alongside GLP-1 is what makes tirzepatide a co-agonist rather than a single-target compound. The research question it answers is what the two arms do together that neither does alone.
why it's the reference compound
Because the dual-agonist class has the deepest research record in this space, tirzepatide is the comparator of choice. The triple agonist retatrutide adds a glucagon-receptor arm on top of this dual profile — see retatrutide vs tirzepatide for the side-by-side.
verifying identity and purity
Every tirzepatide research pen ships with an independent, batch-specific certificate of analysis reporting LC-MS identity and HPLC purity. Verify the batch before any research use — see how to read a COA and what HPLC purity means.
research use only
This compound is supplied strictly for in-vitro and laboratory research use only. It is not a medicine, is not for human or veterinary consumption, and nothing on this page is dosing, medical or treatment guidance. Any effect described is stated in the context of published research, not a claim about use.
where to find Tirzepatide
Tirzepatide is supplied in the following research pens — pre-filled, batch-numbered and independently assayed. Save one to your list and we'll email you the moment it's available in your country.
